355 related articles for article (PubMed ID: 27785980)
21. Concordance between genomic alterations assessed by next-generation sequencing in tumor tissue or circulating cell-free DNA.
Chae YK; Davis AA; Carneiro BA; Chandra S; Mohindra N; Kalyan A; Kaplan J; Matsangou M; Pai S; Costa R; Jovanovic B; Cristofanilli M; Platanias LC; Giles FJ
Oncotarget; 2016 Oct; 7(40):65364-65373. PubMed ID: 27588476
[TBL] [Abstract][Full Text] [Related]
22. Genomic Profiling of Aggressive Thyroid Cancer in Association With its Clinicopathological Characteristics.
Kim JH; Jeong JY; Seo AN; Park NJ; Kim M; Park JY
In Vivo; 2022; 36(1):111-120. PubMed ID: 34972706
[TBL] [Abstract][Full Text] [Related]
23. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers.
Landa I; Ibrahimpasic T; Boucai L; Sinha R; Knauf JA; Shah RH; Dogan S; Ricarte-Filho JC; Krishnamoorthy GP; Xu B; Schultz N; Berger MF; Sander C; Taylor BS; Ghossein R; Ganly I; Fagin JA
J Clin Invest; 2016 Mar; 126(3):1052-66. PubMed ID: 26878173
[TBL] [Abstract][Full Text] [Related]
24. CLM29 and CLM24, pyrazolopyrimidine derivatives, have antitumoral activity in vitro in anaplastic thyroid cancer, with or without BRAF mutation.
Fallahi P; Ferrari SM; La Motta C; Materazzi G; Bocci G; Da Settimo F; Miccoli P; Antonelli A
Endocrine; 2016 Jul; 53(1):136-44. PubMed ID: 26286966
[TBL] [Abstract][Full Text] [Related]
25. Anaplastic thyroid carcinoma: an epidemiologic, histologic, immunohistochemical, and molecular single-institution study.
Deeken-Draisey A; Yang GY; Gao J; Alexiev BA
Hum Pathol; 2018 Dec; 82():140-148. PubMed ID: 30075157
[TBL] [Abstract][Full Text] [Related]
26. Personalized therapy in patients with anaplastic thyroid cancer: targeting genetic and epigenetic alterations.
Smith N; Nucera C
J Clin Endocrinol Metab; 2015 Jan; 100(1):35-42. PubMed ID: 25347569
[TBL] [Abstract][Full Text] [Related]
27. Molecular Profile of Advanced Thyroid Carcinomas by Next-Generation Sequencing: Characterizing Tumors Beyond Diagnosis for Targeted Therapy.
Chen H; Luthra R; Routbort MJ; Patel KP; Cabanillas ME; Broaddus RR; Williams MD
Mol Cancer Ther; 2018 Jul; 17(7):1575-1584. PubMed ID: 29695638
[TBL] [Abstract][Full Text] [Related]
28. Diagnostic Utility of Next-Generation Sequencing in Circulating Free DNA and a Comparison With Matched Tissue in Gallbladder Carcinoma.
Mishra S; Srivastava P; Pandey A; Shukla S; Agarwal A; Husain N
Lab Invest; 2024 Feb; 104(2):100301. PubMed ID: 38092180
[TBL] [Abstract][Full Text] [Related]
29. Unique mutation patterns in anaplastic thyroid cancer identified by comprehensive genomic profiling.
Khan SA; Ci B; Xie Y; Gerber DE; Beg MS; Sherman SI; Cabanillas ME; Busaidy NL; Burtness BA; Heilmann AM; Bailey M; Ross JS; Sher DJ; Ali SM
Head Neck; 2019 Jun; 41(6):1928-1934. PubMed ID: 30758123
[TBL] [Abstract][Full Text] [Related]
30. Mutation based approaches to the treatment of anaplastic thyroid cancer.
McCrary HC; Aoki J; Huang Y; Chadwick B; Kerrigan K; Witt B; Hunt JP; Abraham D
Clin Endocrinol (Oxf); 2022 May; 96(5):734-742. PubMed ID: 35067961
[TBL] [Abstract][Full Text] [Related]
31. Anaplastic thyroid cancer: outcome and the mutation/expression profiles of potential targets.
Wu H; Sun Y; Ye H; Yang S; Lee SL; de las Morenas A
Pathol Oncol Res; 2015 Jul; 21(3):695-701. PubMed ID: 25588542
[TBL] [Abstract][Full Text] [Related]
32. Clinicopathologic Features of Mismatch Repair-Deficient Anaplastic Thyroid Carcinomas.
Wong KS; Lorch JH; Alexander EK; Nehs MA; Nowak JA; Hornick JL; Barletta JA
Thyroid; 2019 May; 29(5):666-673. PubMed ID: 30869569
[No Abstract] [Full Text] [Related]
33. Metastatic Anaplastic Thyroid Carcinoma in Complete Remission: Morphological, Molecular, and Clinical Work-Up of a Rare Case.
Stenman A; Hellgren LS; Jatta K; Hysek M; Zemmler M; Altena R; Nilsson IL; Bränström R; Zedenius J; Juhlin CC
Endocr Pathol; 2020 Mar; 31(1):77-83. PubMed ID: 32016808
[TBL] [Abstract][Full Text] [Related]
34. Anaplastic carcinoma of the thyroid arising more often from follicular carcinoma than papillary carcinoma.
Wang HM; Huang YW; Huang JS; Wang CH; Kok VC; Hung CM; Chen HM; Tzen CY
Ann Surg Oncol; 2007 Oct; 14(10):3011-8. PubMed ID: 17638058
[TBL] [Abstract][Full Text] [Related]
35. Integrative analysis of genomic and transcriptomic characteristics associated with progression of aggressive thyroid cancer.
Yoo SK; Song YS; Lee EK; Hwang J; Kim HH; Jung G; Kim YA; Kim SJ; Cho SW; Won JK; Chung EJ; Shin JY; Lee KE; Kim JI; Park YJ; Seo JS
Nat Commun; 2019 Jun; 10(1):2764. PubMed ID: 31235699
[TBL] [Abstract][Full Text] [Related]
36. Advances in the management of anaplastic thyroid carcinoma: transforming a life-threatening condition into a potentially treatable disease.
Califano I; Smulever A; Jerkovich F; Pitoia F
Rev Endocr Metab Disord; 2024 Feb; 25(1):123-147. PubMed ID: 37648897
[TBL] [Abstract][Full Text] [Related]
37. Genomic Alterations in Fatal Forms of Non-Anaplastic Thyroid Cancer: Identification of
Ibrahimpasic T; Xu B; Landa I; Dogan S; Middha S; Seshan V; Deraje S; Carlson DL; Migliacci J; Knauf JA; Untch B; Berger MF; Morris L; Tuttle RM; Chan T; Fagin JA; Ghossein R; Ganly I
Clin Cancer Res; 2017 Oct; 23(19):5970-5980. PubMed ID: 28634282
[No Abstract] [Full Text] [Related]
38. Mutation-based, short-term "neoadjuvant" treatment allows resectability in stage IVB and C anaplastic thyroid cancer.
Maurer E; Eilsberger F; Wächter S; Riera Knorrenschild J; Pehl A; Holzer K; Neubauer A; Luster M; Bartsch DK
Eur Arch Otorhinolaryngol; 2023 Mar; 280(3):1509-1518. PubMed ID: 36637521
[TBL] [Abstract][Full Text] [Related]
39. Response to Targeted Therapy in BRAF Mutant Anaplastic Thyroid Cancer.
Agarwal R; Wang J; Wilson K; Barrett W; Morris JC
J Natl Compr Canc Netw; 2016 Oct; 14(10):1203-1207. PubMed ID: 27697975
[TBL] [Abstract][Full Text] [Related]
40. Sorafenib inhibits vascular endothelial cell proliferation stimulated by anaplastic thyroid cancer cells regardless of BRAF mutation status.
Ishihara S; Onoda N; Noda S; Asano Y; Tauchi Y; Morisaki T; Kashiwagi S; Takashima T; Ohira M
Int J Oncol; 2019 Nov; 55(5):1069-1076. PubMed ID: 31545405
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
